Early data from the first clinical trial of MOv18 IgE corroborate our results, as both rapid plasma clearance of the IgE and reduction in the tumor biomarker CA-125 were observed.21 As a practical consequence, blood sampling in patients may not be an ideal guide for dosing IgE-based therapies, and typical immunotherapy dosing schedules consisting of a loading dose followed by maintenance doses may not be appropriate. The gene discussed is IGHE; the disease is neoplasm.